PMEL and uveal melanoma: Notable examples include tebentafusp, a gp100×CD3 TCE targeting HLA-A*0201/gp100 complexes that was recently approved for uveal melanoma (44), and tarlatamab, a DLL3×CD3 TCE that was recently approved for small cell lung cancer (45).